Releases

Date Title and Summary Additional Formats
Toggle Summary Afgørelse fra amerikansk distriktsdomstol i Veloxis retssag
Selskabsmeddelelse nr. 15/2015     Til: NASDAQ OMX Copenhagen A/S                      Hørsholm, 12. juni 2015       Afgørelse fra amerikansk distriktsdomstol i Veloxis retssag   Amerikansk distriktsdomstol afgør, at Envarsus ® XR er afskåret for de novo anvendelse Veloxis indsender
View HTML
Toggle Summary Alastair McEwan Steps Down as Chief Operating Officer of Veloxis Pharmaceuticals A/S
Company Release no. 20/2017   To: NASDAQ Copenhagen A/S                                     Copenhagen, Denmark, 20 September 2017   Alastair McEwan Steps Down as Chief Operating Officer of Veloxis Pharmaceuticals A/S Veloxis Pharmaceuticals A/S (NASDAQ: VELO) announced today that Alastair McEwan
View HTML
Toggle Summary Amerikansk distriktsdomstol fastlægger tidsplan for skriftvekslinger i Veloxis' retssag
Selskabsmeddelelse nr. 2/2015     Til: NASDAQ OMX Copenhagen A/S                              Hørsholm, den 14. januar 2015     Amerikansk distriktsdomstol fastlægger tidsplan for skriftvekslinger i Veloxis' retssag   Veloxis Pharmaceuticals A/S (OMX: VELO) (Veloxis) har i dag bekræftet, at
View HTML
Toggle Summary Announcement no. 10/2006 LifeCycle Pharma, FDA Accepts LifeCycle Pharma A/S' New Drug Application for LCP-FenoChol for Review
FDA accepts LifeCycle Pharma A/S' New Drug Application for LCP-FenoChol (fenofibrate) for review.
View HTML
Toggle Summary Announcement no. 10/2007 LifeCycle Pharma A/S Announces Financial Results for the first 3 Months of 2007
Announcement no. 10/2007 To OMX Nordic Exchange. Hørsholm, Denmark, 9 May 2007 LifeCycle Pharma Announces Financial Results for the first 3 Months of 2007 Summary: LifeCycle Pharma announces financial results for the first three months of 2007 LifeCycle Pharma A/S (OMX:LCP) announced today
View HTML
Toggle Summary Announcement no. 11/2006 LifeCycle Pharma, issues warrants
LifeCycle Pharma A/S issues 32,381 warrants to CEO Flemming Ørnskov
View HTML
Toggle Summary Announcement no. 11/2007 LifeCycle Pharma A/S - report Pursuant to the Danish Securities Trading Act, Section 28(a)
Announcement no. 11/2007 To OMX Nordic Exchange Hørsholm, Denmark, 9 May 2007 LIFECYCLE PHARMA A/S - REPORT PURSUANT TO THE DANISH SECURITIES TRADING ACT, SECTION 28(a) Summary: Report of transactions in LifeCycle Pharma shares and related securities by persons discharging managerial
View HTML
Toggle Summary Announcement no. 12/2007 LifeCycle Pharma Receives US Patent for its MeltDose® Technology
Announcement no. 12/2007 To OMX Nordic Exchange Hørsholm, Denmark, 15 May 2007 LifeCycle Pharma Receives US Patent for its MeltDose® Technology Summary: LifeCycle Pharma receives US patent for its MeltDose® Technology LifeCycle Pharma A/S (OMX:LCP) announced today the issuance of a patent for its
View HTML
Toggle Summary Announcement no. 13/2007 LifeCycle Pharma Announces Positive Phase I Clinical Results - Heads into US Phase II Clinical Trials for Organ Transplantation
Announcement no. 13/2007 To OMX Nordic Exchange Hørsholm, Denmark, 31 May 2007 LifeCycle Pharma Announces Positive Phase I Clinical Results for its Transplantation Product Candidate, LCP-Tacro - Heads into US Phase II Clinical Trials for Organ Transplantation Summary: LifeCycle Pharma announces
View HTML
Toggle Summary Announcement no. 14/2007 LifeCycle Pharma A/S' total capital and the total number of voting rights
Announcement no. 14/2007 To OMX Nordic Exchange Hørsholm, Denmark, 1 June 2007 LifeCycle Pharma A/S' total capital and the total number of voting rights Hørsholm, Denmark, 1 June 2007; In accordance with section 17 (2) of the Danish Executive Order no.
View HTML